Table 2 Frequencies of positive antibodies (anti-GAD, anti-TPO, anti-Tg), thyroid diseases, thyroid treatment and Levothyroxine supplementation
From: Thyroid disease in insulin-treated patients with type 2 diabetes: a retrospective study
Group 1 | Group 2 | Group 3 | Total | Statistical significance | |
|---|---|---|---|---|---|
Anti – GAD | 0 (0.0%) | 0 (0.0%) | 1 (3.0%) | 1 (2.3%) | ns |
Anti – TPO | 2 (10.0%) | 3 (50.0%) | 24 (24.5%) | 29 (23.4%) | ns |
Anti – Tg | 2 (10.0%) | 2 (33.3%) | 18 (18.6%) | 22 (17.9%) | ns |
Hypothyroidism | 13 (28.3%) | 4 (44.4%) | 54 (40.6%) | 71 (37.8%) | ns |
Hyperthyroidism | 8 (17.4%) | 3 (33.3%) | 55 (41.4%) | 66 (35.1%) | p < 0.05 |
AITD | 13 (28.3%) | 4 (44.4%) | 28 (21.1%) | 45 (23.9%) | ns |
Goitre | 28 (60.9%) | 1 (11.1%) | 51 (38.3%) | 80 (42.6%) | p < 0.01 |
With AITD | 5 (10.9%) | 0 (0.0%) | 6 (4.5%) | 11 (5.9%) | ns |
Without AITD | 23 (50.0%) | 1 (11.1%) | 45 (33.8%) | 69 (36.7%) | p < 0.05 |
AFT | 2 (4.4%) | 0 (0.0%) | 8 (6.1%) | 10 (5.3%) | ns |
Carcinoma | 0 (0.0%) | 1 (11.1%) | 3 (2.3%) | 4 (2.1%) | ns |
Thyroid treatment | 45 (97.8%) | 6 (66.7%) | 90 (67.7%) | 141 (75.0%) | p < 0.001 |
Levothyroxine | 41 (89.1%) | 5 (55.6%) | 69 (51.9%) | 115 (61.2%) | p < 0.001 |